{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:33:25Z","timestamp":1789544005495,"version":"build-2803163510"},"reference-count":83,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Ulcerative colitis (UC) is part of the inflammatory bowels diseases, and moderate to severe UC patients can be treated with anti-tumour necrosis \u03b1 monoclonal antibodies, including infliximab (IFX). Even though treatment of UC patients by IFX has been in place for over a decade, many gaps in modelling of IFX PK in this population remain. This is even more true for acute severe UC (ASUC) patients for which early prediction of IFX pharmacokinetic (PK) could highly improve treatment outcome. Thus, this review aims to compile and analyse published population PK models of IFX in UC and ASUC patients, and to assess the current knowledge on disease activity impact on IFX PK. For this, a semi-systematic literature search was conducted, from which 26 publications including a population PK model analysis of UC patients receiving IFX therapy were selected. Amongst those, only four developed a model specifically for UC patients, and only three populations included severe UC patients. Investigations of disease activity impact on PK were reported in only 4 of the 14 models selected. In addition, the lack of reported model codes and assessment of predictive performance make the use of published models in a clinical setting challenging. Thus, more comprehensive investigation of PK in UC and ASUC is needed as well as more adequate reports on developed models and their evaluation in order to apply them in a clinical setting.<\/jats:p>","DOI":"10.3390\/pharmaceutics14102095","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T01:21:07Z","timestamp":1665364867000},"page":"2095","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Ulcerative Colitis and Acute Severe Ulcerative Colitis Patients Are Overlooked in Infliximab Population Pharmacokinetic Models: Results from a Comprehensive Review"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1106-2146","authenticated-orcid":false,"given":"Alix","family":"D\u00e9maris","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universit\u00e4t Berlin, Kelchstrasse 31, 12169 Berlin, Germany"},{"name":"Graduate Research Training Program PharMetrX, 12169 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella S. K.","family":"Widigson","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universit\u00e4t Berlin, Kelchstrasse 31, 12169 Berlin, Germany"},{"name":"Graduate Research Training Program PharMetrX, 12169 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan F. K. F.","family":"Ilvemark","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Copenhagen University Hospital Herlev, 2730 Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3898-4212","authenticated-orcid":false,"given":"Casper","family":"Steenholdt","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Copenhagen University Hospital Herlev, 2730 Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob B.","family":"Seidelin","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Copenhagen University Hospital Herlev, 2730 Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilhelm","family":"Huisinga","sequence":"additional","affiliation":[{"name":"Institute of Mathematics, Universit\u00e4t Potsdam, 14476 Potsdam, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-607X","authenticated-orcid":false,"given":"Robin","family":"Michelet","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universit\u00e4t Berlin, Kelchstrasse 31, 12169 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda B. S.","family":"Aulin","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universit\u00e4t Berlin, Kelchstrasse 31, 12169 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Kloft","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universit\u00e4t Berlin, Kelchstrasse 31, 12169 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"key":"ref_1","first-page":"2066","article-title":"Inflammatory Bowel Disease","volume":"361","author":"Abraham","year":"2009","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1053\/j.gastro.2011.01.055","article-title":"Epidemiology and Natural History of Inflammatory Bowel Diseases","volume":"140","author":"Cosnes","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5009\/gnl18203","article-title":"Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease","volume":"14","author":"Nakase","year":"2020","journal-title":"Gut Liver"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/ibd.20520","article-title":"Use of the Noninvasive Components of the Mayo Score to Assess Clinical Response in Ulcerative Colitis","volume":"14","author":"Lewis","year":"2008","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/apt.13948","article-title":"Defining Endoscopic Response and Remission in Ulcerative Colitis Clinical Trials: An International Consensus","volume":"45","author":"Vuitton","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis. A Randomized Study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/gut.43.1.29","article-title":"A Simple Clinical Colitis Activity Index","volume":"43","author":"Walmsley","year":"1998","journal-title":"Gut"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cgh.2017.06.016","article-title":"Natural History of Adult Ulcerative Colitis in Population-Based Cohorts: A Systematic Review","volume":"16","author":"Fumery","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/gut.4.4.299","article-title":"The Course and Prognosis of Ulcerative Colitis","volume":"4","author":"Edwards","year":"1963","journal-title":"Gut"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/ecco-jcc\/jjy154","article-title":"Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-Based Inception Cohort-An Epi-IBD Study","volume":"13","author":"Burisch","year":"2019","journal-title":"J. Crohns Colitis"},{"key":"ref_11","first-page":"652","article-title":"Predictors of Aggressive Inflammatory Bowel Disease","volume":"7","author":"Yarur","year":"2011","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/SLA.0000000000002628","article-title":"Postoperative Mortality After Nonelective Surgery for Inflammatory Bowel Disease Patients in the Era of Biologics","volume":"269","author":"Justiniano","year":"2019","journal-title":"Ann. Surg."},{"key":"ref_13","first-page":"359","article-title":"Response to First Intravenous Steroid Therapy Determines the Subsequent Risk of Colectomy in Ulcerative Colitis Patients","volume":"20","author":"Farkas","year":"2011","journal-title":"J. Gastrointestin Liver Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nrgastro.2014.126","article-title":"IBD. Sequential Rescue Therapy in Steroid-Refractory Ulcerative Colitis","volume":"11","author":"Gionchetti","year":"2014","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","article-title":"Cortisone in Ulcerative Colitis; Final Report on a Therapeutic Trial","volume":"2","author":"Truelove","year":"1955","journal-title":"Br. Med. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2147\/JIR.S165330","article-title":"Role of Biologics and Biosimilars in Inflammatory Bowel Disease: Current Trends and Future Perspectives","volume":"11","author":"Rawla","year":"2018","journal-title":"J. Inflamm. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/0161-5890(93)90106-L","article-title":"Construction and Initial Characterization of a Mouse-Human Chimeric Anti-TNF Antibody","volume":"30","author":"Knight","year":"1993","journal-title":"Mol. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s40262-017-0627-0","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease","volume":"57","author":"Hemperly","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology Consensus Guidelines on the Management of Inflammatory Bowel Disease in Adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"ref_21","unstructured":"(2022, September 05). Steroid\/Thiopurine Refractory UC|ECCO E-Guide. Available online: http:\/\/www.e-guide.ecco-ibd.eu\/algorithm\/steroid-thiopurine-refractory-uc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/apt.16723","article-title":"Trends in the Use of Biologicals and Their Treatment Outcomes among Patients with Inflammatory Bowel Diseases\u2014A Danish Nationwide Cohort Study","volume":"55","author":"Zhao","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_23","unstructured":"(2013). REMICADE (Infliximab) [Package Insert], Janssen Biotech, Inc.. Available online: https:\/\/www.remicade.com\/."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.cgh.2018.06.031","article-title":"Effect of Accelerated Infliximab Induction on Short- and Long-Term Outcomes of Acute Severe Ulcerative Colitis: A Retrospective Multicenter Study and Meta-Analysis","volume":"17","author":"Nalagatla","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.14309\/ajg.0000000000001396","article-title":"A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease","volume":"116","author":"Cheifetz","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.gastro.2017.07.031","article-title":"American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases","volume":"153","author":"Herfarth","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/gut.2009.201533","article-title":"The Immunogenic Part of Infliximab Is the F(Ab\u2019)2, but Measuring Antibodies to the Intact Infliximab Molecule Is More Clinically Useful","volume":"60","author":"Yavzori","year":"2011","journal-title":"Gut"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ajg.2012.363","article-title":"Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients with Inflammatory Bowel Disease (IBD): A Meta-Analysis","volume":"108","author":"Nanda","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00535-017-1324-3","article-title":"hu Systematic Review with Meta-Analysis: Loss of Response and Requirement of Anti-TNF\u03b1 Dose Intensification in Crohn\u2019s Disease","volume":"52","author":"Qiu","year":"2017","journal-title":"J. Gastroenterol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/cpt.2049","article-title":"Perspectives on Model-Informed Precision Dosing in the Digital Health Era: Challenges, Opportunities, and Recommendations","volume":"109","author":"Kluwe","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/cpt.659","article-title":"Why Has Model-Informed Precision Dosing Not Yet Become Common Clinical Reality? Lessons from the Past and a Roadmap for the Future","volume":"101","author":"Darwich","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/cpt.2202","article-title":"From Therapeutic Drug Monitoring to Model-Informed Precision Dosing for Antibiotics","volume":"109","author":"Wicha","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2165\/00003088-200746030-00003","article-title":"Are Population Pharmacokinetic and\/or Pharmacodynamic Models Adequately Evaluated? A Survey of the Literature from 2002 to 2004","volume":"46","author":"Brendel","year":"2007","journal-title":"Clin. Pharmacokinet."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e9982","DOI":"10.15252\/msb.20209982","article-title":"Reproducibility in Systems Biology Modelling","volume":"17","author":"Tiwari","year":"2021","journal-title":"Mol. Syst. Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1097\/MIB.0000000000000212","article-title":"Patient Factors That Increase Infliximab Clearance and Shorten Half-Life in Inflammatory Bowel Disease: A Population Pharmacokinetic Study","volume":"20","author":"Dotan","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/FTD.0000000000000476","article-title":"External Evaluation of Population Pharmacokinetic Models of Infliximab in Patients with Inflammatory Bowel Disease","volume":"40","author":"Santacana","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/cpt.1429","article-title":"Pharmacokinetic Parameters of Infliximab Influence the Rate of Relapse After De-Escalation in Adults With Inflammatory Bowel Diseases","volume":"106","author":"Petitcollin","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/bcp.14410","article-title":"Bayes-Based Dosing of Infliximab in Inflammatory Bowel Diseases: Short-Term Efficacy","volume":"87","author":"Guardiola","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_40","first-page":"590","article-title":"Usefulness of Population Pharmacokinetics to Optimize the Dosage Regimen of Infliximab in Inflammatory Bowel Disease Patients","volume":"112","year":"2020","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/apt.16609","article-title":"Population Pharmacokinetics of Subcutaneous Infliximab CT-P13 in Crohn\u2019s Disease and Ulcerative Colitis","volume":"54","author":"Hanzel","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/ibd\/izab285","article-title":"Dashboard-Driven Accelerated Infliximab Induction Dosing Increases Infliximab Durability and Reduces Immunogenicity","volume":"28","author":"Dubinsky","year":"2022","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"105317","DOI":"10.1016\/j.ejps.2020.105317","article-title":"Prediction of Treatment Failure during Infliximab Induction Therapy in Inflammatory Bowel Disease Patients Based on Pharmacokinetic and Pharmacodynamic Modeling","volume":"150","author":"Kimura","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1208\/s12248-017-0082-8","article-title":"Infliximab Maintenance Dosing in Inflammatory Bowel Disease: An Example for In Silico Assessment of Adaptive Dosing Strategies","volume":"19","author":"Wojciechowski","year":"2017","journal-title":"AAPS J."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Faelens, R., Wang, Z., Bouillon, T., Declerck, P., Ferrante, M., Vermeire, S., and Dreesen, E. (2021). Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative Colitis. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13101623"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.cgh.2018.10.036","article-title":"Infliximab Exposure-Response Relationship and Thresholds Associated With Endoscopic Healing in Patients With Ulcerative Colitis","volume":"17","author":"Jeyarajah","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/bdd.2198","article-title":"Prediction of Clinical Effects of Infliximab Administered for Inflammatory Bowel Disease Based on Pharmacokinetic and Pharmacodynamic Modeling","volume":"40","author":"Kimura","year":"2019","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/FTD.0b013e318180e300","article-title":"Infliximab Pharmacokinetics in Inflammatory Bowel Disease Patients","volume":"30","author":"Ternant","year":"2008","journal-title":"Ther. Drug Monit."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00228-009-0718-4","article-title":"Population Pharmacokinetic Analysis of Infliximab in Patients with Ulcerative Colitis","volume":"65","author":"Fasanmade","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/apt.13299","article-title":"Population Pharmacokinetics of Infliximab in Patients with Inflammatory Bowel Disease: Potential Implications for Dosing in Clinical Practice","volume":"42","author":"Buurman","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1080\/19420862.2016.1216741","article-title":"The Underlying Inflammatory Chronic Disease Influences Infliximab Pharmacokinetics","volume":"8","author":"Passot","year":"2016","journal-title":"MAbs"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/MIB.0000000000001043","article-title":"A Real-Life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease","volume":"23","author":"Brandse","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1208\/s12248-016-9994-y","article-title":"Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients","volume":"19","author":"Dubinsky","year":"2017","journal-title":"AAPS J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/jcph.1069","article-title":"Prediction of Individual Serum Infliximab Concentrations in Inflammatory Bowel Disease by a Bayesian Dashboard System","volume":"58","author":"Eser","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1093\/ecco-jcc\/jjy028","article-title":"Accelerated Clearance of Infliximab Is Associated with Treatment Failure in Patients with Corticosteroid-Refractory Acute Ulcerative Colitis","volume":"12","author":"Kevans","year":"2018","journal-title":"J. Crohns Colitis"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/bcp.13859","article-title":"Optimising Infliximab Induction Dosing for Patients with Ulcerative Colitis","volume":"85","author":"Dreesen","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10928-019-09652-5","article-title":"Tumor Necrosis Factor-Mediated Disposition of Infliximab in Ulcerative Colitis Patients","volume":"46","author":"Berends","year":"2019","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/ibd\/izz143","article-title":"Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease","volume":"26","author":"Bauman","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1111\/bcp.14648","article-title":"Quantitative Relationship between Infliximab Exposure and Inhibition of C-Reactive Protein Synthesis to Support Inflammatory Bowel Disease Management","volume":"87","author":"Grisic","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Konecki, C., Feliu, C., Cazaubon, Y., Giusti, D., Tonye-Libyh, M., Brixi, H., Cadiot, G., Biron, A., and Djerada, Z. (2021). External Evaluation of Population Pharmacokinetic Models and Bayes-Based Dosing of Infliximab. Pharmaceutics.","DOI":"10.3390\/pharmaceutics13081191"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Schr\u00e4pel, C., Kovar, L., Selzer, D., Hofmann, U., Tran, F., Reinisch, W., Schwab, M., and Lehr, T. (2021). External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel Disease. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13091368"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","article-title":"Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies","volume":"49","author":"Keizer","year":"2010","journal-title":"Clin. Pharmacokinet."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of Monoclonal Antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.clinthera.2011.06.002","article-title":"Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn\u2019s Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials","volume":"33","author":"Fasanmade","year":"2011","journal-title":"Clin. Ther."},{"key":"ref_65","first-page":"1177","article-title":"Population Pharmacokinetic Analysis of Infliximab in Pediatrics Using Integrated Data from Six Clinical Trials","volume":"203","author":"Xu","year":"2012","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40262-013-0114-1","article-title":"Reporting a Population Pharmacokinetic-Pharmacodynamic Study: A Journal\u2019s Perspective","volume":"53","author":"Jamsen","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"ref_67","unstructured":"US Food And Drug Administration (FDA) (2022). Population Pharmacokinetics: Guidance for Industry."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/ecco-jcc\/jjaa265","article-title":"Predicting Outcome in Acute Severe Colitis-Controversies in Clinical Practice in 2021","volume":"15","author":"Gupta","year":"2021","journal-title":"J. Crohns Colitis"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1517\/17425250902992901","article-title":"Target-Mediated Drug Disposition Model: Approximations, Identifiability of Model Parameters and Applications to the Population Pharmacokinetic\u2013Pharmacodynamic Modeling of Biologics","volume":"5","author":"Gibiansky","year":"2009","journal-title":"Expert Opin. drug Metab. Toxicol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"taac053","DOI":"10.1093\/jtm\/taac053","article-title":"Tumour Necrosis Factor-\u03b1 as a Prognostic Biomarker of Severe Malaria: A Systematic Review and Meta-Analysis","volume":"29","author":"Mahittikorn","year":"2022","journal-title":"J. Travel Med."},{"key":"ref_72","first-page":"e15314","article-title":"Serum Tumor Necrosis Factor-Alpha as a Competent Biomarker for Evaluation of Disease Activity in Early Rheumatoid Arthritis","volume":"13","author":"Illahi","year":"2021","journal-title":"Cureus"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00432-014-1592-8","article-title":"Plasma Tumor Necrosis Factor-\u03b1 and C-Reactive Protein as Biomarker for Survival in Head and Neck Squamous Cell Carcinoma","volume":"140","author":"Andersson","year":"2014","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1208\/s12248-016-9989-8","article-title":"Magnitude of Increased Infliximab Clearance Imposed by Anti-Infliximab Antibodies in Crohn\u2019s Disease Is Determined by Their Concentration","volume":"19","author":"Edlund","year":"2017","journal-title":"AAPS J."},{"key":"ref_75","unstructured":"Brekkan, A., Lacroix, B., Lledo-Garcia, R., J\u00f6nsson, S., Karlsson, M.O., and Plan, E.L. (2022, July 28). Characterization of Anti-Drug Antibodies Using a Bivariate Mixed Hidden Markov Model. Available online: https:\/\/www.page-meeting.org\/default.asp?abstract=8664."},{"key":"ref_76","unstructured":"D\u00e9maris, A., Plan, E.L., Huisinga, W., Aulin, L.B.S., Lee, S.H., Lee, J.H., Reinisch, W., Michelet, R., and Kloft, C. (2022, July 28). Towards Understanding Anti-Infliximab Antibody Development to Predict Crohn\u2019s Disease Patients\u2019 Underlying Immunogenicity Status. Available online: https:\/\/www.page-meeting.org\/default.asp?abstract=10212."},{"key":"ref_77","unstructured":"Leisegang, R.F., Silber Baumann, H.E., Lennon-Chrimes, S., Ito, H., and Plan, E.L. (2022, July 28). Immunogenicity Dynamics and Covariate Effects after Satralizumab Administration Predicted with a Hidden Markov Model. Available online: https:\/\/www.page-meeting.org\/default.asp?abstract=10049."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/ecco-jcc\/jjaa057","article-title":"Systematic Review of Development and Content Validity of Patient-Reported Outcome Measures in Inflammatory Bowel Disease: Do We Measure What We Measure?","volume":"14","author":"Koopmann","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/ajg.2016.59","article-title":"Poor Correlation Between Clinical Disease Activity and Mucosal Inflammation, and the Role of Psychological Comorbidity, in Inflammatory Bowel Disease","volume":"111","author":"Gracie","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/flgastro-2016-100685","article-title":"Use of Anti-TNF Drug Levels to Optimise Patient Management","volume":"7","author":"Papamichael","year":"2016","journal-title":"Frontline Gastroenterol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn\u2019s Disease","volume":"348","author":"Baert","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/clpt.2012.122","article-title":"Model-Based Meta-Analysis: An Important Tool for Making Quantitative Decisions During Drug Development","volume":"92","author":"Mould","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/cpt.1462","article-title":"Model-Based Meta-Analysis: Optimizing Research, Development, and Utilization of Therapeutics Using the Totality of Evidence","volume":"106","author":"Upreti","year":"2019","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/10\/2095\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:44:49Z","timestamp":1760143489000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/10\/2095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":83,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["pharmaceutics14102095"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics14102095","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]}}}